Recent advances in pulmonary drug delivery using large, porous inhaled particles

Journal of Applied Physiology

Volumn 85, Issue 2, 1998, Pages 379-385

  Edwards, David A ^a,c   Ben Jebria, Abdelaziz ^a   Langer, Robert ^b  

^a Pennsylvania State University   (United States)

^b USA   (United States)

^c Advanced Inhalation Research   (United States)

Author keywords

Aerosol particles; Inhalation therapies; Respiratory illness

Indexed keywords

ALPHA 1 ANTITRYPSIN; CALCITONIN; GLUCAGON; GROWTH HORMONE; IMMUNOGLOBULIN G; INSULIN; LEUPRORELIN; PARATHYROID HORMONE[1-34]; POLYGLACTIN;

AEROSOL; BIOAVAILABILITY; BULK DENSITY; DRUG PENETRATION; INHALATIONAL DRUG ADMINISTRATION; LUNG CLEARANCE; PARTICLE SIZE; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SOLUBILITY; SURFACE PROPERTY;

EID: 0031904113     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.1998.85.2.379     Document Type: Review

References (38)

1. Adjei, L., and J. Garren. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm. Res. 7: 565-569, 1990.
2. Altschuler, B., L. Yarmus, E. D. Palmes, and N. Nelson. Aerosol deposition in the human respiratory tract. Am. Med. Assoc. Arch. Industr. Health 15: 293-303, 1957.
3. Clark, A. R., and M. Egan. Modelling the deposition of inhaled powdered drug aerosols. J. Aerosol Sci. 25: 175-186, 1994.
4. Clay, M. M., D. Pavia, and S. W. Clarke. Effect of aerosol particle size on bronchodilation with nebulized terbutaline in asthmatic subjects. Thorax 41: 364-368, 1986.
5. Davies, C. N., J. Heyder, and M. C. Subba Ramu. Breathing of half-micron aerosols. I. Experimental. J. Appl. Physiol. 32: 591-600, 1972.
6. Edwards, D. A., J. Hanes, G. Caponnetti, J. Hrkach, A. Ben-Jebria, M.-L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer. Large porous particles for pulmonary drug delivery. Science 276: 1868-1871, 1997.
7. Folkesson, H. G., B. R. Westrom, and B. W. Karlsson. Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. Acta Physiol. Scand. 139: 347-354, 1990.
8. Gehr, P., M. Geiser, V. Im Hof, S. Schurch, U. Waber and M. Baumann. Surfactant and inhaled particles in the conducting airways: structural, stereological, and biophysical aspects. Microsc. Res. Tech. 26: 423-436, 1993.
9. Gerrity, T. R., P. S. Lee, F. J. Hass, A. Marinelli, P. Werner, and R. V. Lourenco. Calculated deposition of inhaled particles in the airway generations of normal subjects. J. Appl. Physiol. 47: 867-873, 1979.
10. Gonda, I. Physicochemical principles in aerosol delivery. In: Topics in Pharmaceutical Sciences 1991, edited by D. J. A. Crommelin and K. K. Midha. Stuttgart, Germany: Medpharm Scientific, 1992, p. 95-115.
11. Gonda, I. Targeting by deposition. In: Pharmaceutical Inhalation Aerosol Technology, edited by A. J. Hickey. New York: Dekker, 1992, p. 61-82.
12. Heyder, J., L. Armbruster, J. Bebhart, E. Grein, and W. Stahlhofen. Total deposition of aerosol particles in the human respiratory tract for nose and mouth breathing. J. Aerosol Sci. 6: 311-328, 1975.
13. Heyder, J., and G. Rudolf. Mathematical models of particle deposition in the human respiratory tract. J. Aerosol Sci. 15: 697-707, 1984.
14. Hickey, A. J., and R. M. Evans. Aerosol generation from propellant-driven metered dose inhalers. In: Inhalation Aerosols, edited by A. J. Hickey. New York: Dekker, 1996, p. 417-439.
15. Hubbard, R. C., M. A. Casolaro, M. Mitchell, S. E. Sellers, F. Arabia, M. A. Matthay, and R. G. Crystal. Fate of aerosolized recombinant DNA-produced alpha-I-antitrypsin: use of the epithelial surface of the lower respiratory tract to adminster proteins of therapeutic importance. Proc. Natl. Acad. Sci. USA 86: 680-684, 1984.
16. Johnson, M. A., S. P. Newman, R. Bloom, N. Talee, and S. W. Clarke. Delivery of albuterol and ipratropiurnbromide from two nebulizer systems in chronic stable asthma. Chest 96: 6-10, 1989.
17. Landahl, H. D. On the removal of air-borne droplets by the human respiratory tract. I. The lung. Bull. Math. Biophys. 12: 43-56, 1950.
18. Langer, R. Polymer controlled drug delivery systems. Accounts Chem. Res. 26: 537-542, 1993.
19. Muir, D. C. F., and C. N. Davies. The deposition of 0.5 μm diameter aerosols in the lung of man. Ann. Occup. Hyg. 10: 161-174, 1967.
20. Niven, R. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. 12: 151-173, 1995.
21. Niven, R. W. Atomization and nebulization. In: Inhalation Aerosols, edited by A. J. Hickey. New York: Dekker, 1996, p. 273-312.
22. Patton, J. Mechanisms of macromolecule absorption by the lung.Adv. Drug Delivery Res. 19: 3-36, 1996.
23. Patton, J. S., H. J. Fuchs, J. A. Moore, H. Gustafson, G. A. Keller, and A. L. Daugherty. Pulmonary delivery of peptide and protein drugs. Proc. Int. Symp. Control. Rel. Bioact. Mater. 17: 214-215, 1990.
24. Patton, J. S., P. Trinchero, and R. M. Platz. Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormones. J. Contr. Rel. 28: 79-85, 1994.
25. Phalen, R. F. Inhalation Studies: Foundations and Techniques. Boca Raton, FL: CRC Press, 1984.
26. Richardson, J., T. Bourchard, and C. C. Ferguson. Uptake and transport of exogenous proteins by respiratory epithelium. Lab. Invest. 35: 307-314, 1976.
27. Rudt, S., H. Wesemeyer, and R H. Muller. In vitro phagocytosis assay of nano-and microparticles by chemiluminescence. IV. Effect of surface modification by coating of particles with poloxamine and Antarox CO on the phagocytic uptake. J. Contr. Rel. 25: 123-138, 1993.
28. Ruffin, R. E., M. B. Dolovich, F. A. Oldenburg, and M. T. Newhouse. The preferential deposition of inhaled isoproterenol and propanolol in asthmatic patients. Chest 80: 904-907, 1986.
29. Service, R. F. Drug delivery takes a deep breath. Science 277: 1199-1201, 1997.
30. Smith, P. L. Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery. J. Contr. Rel. 46: 90-106, 1997.
31. Tabata, Y., and Y. Ikada. Effect of size and surface charge of polymer microspheres on their phagocytosis by macrophage. J. Biomed. Mater. Res. 22: 837-842, 1988.
32. Timsina, M. P., G. P. Martin, C. Marriott, P. Ganderton, and M. Yianneskis. Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharmacol. 101: 1-13, 1994.
33. Vincent, J. J. Aerosol Science for Industrial Hygienists. New York: Pergamon, 1995.
34. Wall, D. A. Pulmonary absorption of peptides and proteins. Drug Delivery 2: 1-10, 1995.
35. Wang, J., A. Ben-Jebria, and D. A. Edwards. Controlled-release inhalation aerosols. In: Respiratory Drug Delivery. Buffalo Grove, IL: Interpharm, 1997, vol. VI, p. 187-192.
36. Wigley, F. M., X. J. H. Londono, S. H. Wood, J. C. Shipp, and R. H. Waldman. Insulin across respiratory mucosae by aerosol delivery. Diabetes 20: 552-556, 1971.
37. Zanen, P., L. T. Go, and J.-W. J. Lammers. The optimal particle size for beta adrenergic aerosols in mild asthmatics. Int. J. Pharmacol. 107: 211-217, 1994.
38. Zanen, P., L. T. Go, and J.-W. J. Lammers. The optimal particle size for parasympathicolytic aerosols in mild asthmatics. Int. J. Pharmacol. 4: 111-115, 1995.